NYSE: EWEdwards Lifesciences Corp Stock
$88.61+0.86 (+0.98%)
Updated Apr 24, 2024
EW Price
$88.61
Fair Value Price
N/A
Market Cap
$53.25B
52 Week Low
$60.57
52 Week High
$96.12
P/E
38.36x
P/B
8.01x
P/S
7.7x
PEG
1.44x
Dividend Yield
N/A
Revenue
$6.00B
Earnings
$1.40B
Gross Margin
77%
Operating Margin
26.96%
Profit Margin
23.4%
Debt to Equity
0.4
Operating Cash Flow
$896M
Beta
0.96
Next Earnings
Apr 25, 2024
Ex-Dividend
N/A
Next Dividend
N/A
EW Overview
Edwards Lifesciences Corporation, a medical technology company, specializes in artificial heart valves and hemodynamic monitoring. Its products include surgical valves, transcatheter heart valves, and transcatheter mitral and tricuspid therapies. The company originated the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter. Edwards was founded in 1958 and is headquartered in Irvine, CA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EW scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EW ($88.61) is trading above its intrinsic value of $34.16, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EW is good value based on its earnings relative to its share price (38.36x), compared to the US market average (41.27x)
P/E vs Market Valuation
EW is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more EW due diligence checks available for Premium users.
Be the first to know about important EW news, forecast changes, insider trades & much more!
EW News
Valuation
EW price to earnings (PE)
For valuing profitable companies with steady earnings
Company
38.36x
Industry
30.46x
Market
41.27x
EW is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
EW is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
EW price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.01x
Industry
3.73x
EW is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EW price to earnings growth (PEG)
For valuing profitable companies with growth potential
EW is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
EW's financial health
Profit margin
Revenue
$1.5B
Net Income
$369.9M
Profit Margin
24.1%
EW's Earnings (EBIT) of $1.62B... subscribe to Premium to read more.
Interest Coverage Financials
EW's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.4B
Liabilities
$2.6B
Debt to equity
0.4
EW's short-term assets ($4.04B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EW's short-term assets ($4.04B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EW's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EW's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$136.6M
Investing
$14.1M
Financing
-$413.2M
EW's operating cash flow ($895.80M)... subscribe to Premium to read more.
Debt Coverage Financials
EW vs Medical Device Stocks
Edwards Lifesciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.